Hologic HOLX releases its next round of earnings this Wednesday, May 1. Here's Benzinga's essential guide to Hologic's second-quarter earnings report.
Earnings and Revenue
Wall Street expects EPS of 57 cents and sales around $806.03 million.
In the same quarter last year, Hologic posted EPS of 53 cents on sales of $789.3 million. The analyst consensus estimate would represent a 7.55 percent increase in the company's EPS figure. Sales would be up 2.12 percent on a year-over-year basis. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2019 | Q4 2018 | Q3 2018 | Q2 2018 | Q1 2018 |
| EPS Estimate | 0.57 | 0.58 | 0.56 | 0.53 | 0.5 |
| EPS Actual | 0.58 | 0.58 | 0.58 | 0.53 | 0.55 |
Stock Performance
Over the last 52-week period, shares are up 17.84 percent. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.
Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. Analysts have been rating Hologic stock as Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
Don't be surprised to see the stock move on comments made during its conference call. Hologic's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here: https://edge.media-server.com/m6/p/e36b8bxx
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
